Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared ...

Fewer than half of donated hearts are ultimately used, researchers said in background notes. One major reason is that there’s ...

The U.S. Food and Drug Administration has approved the humanized monoclonal antibody, Zynyz, (retifanlimab-dlwr) as the first ...

We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for ...

In the EU, GOHIBIC (vilobelimab) has been granted marketing authorization under exceptional circumstances for the treatment ...

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...

Discover the 7 essential nutrients your brain needs to fight Alzheimer's disease. Learn which foods boost memory and protect ...

Angelini is paying $50 million upfront for ex-North American rights to radiprodil, with another $520 million in the offing in ...

announces it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2.5 million (the “Equity Rule”) On May 7, 2025 the Nasdaq Hearings Panel (the ...